Shalit Roy, Tripto-Shkolnik Liana
AACE Clin Case Rep. 2020 Aug 6;6(6):e315-e318. doi: 10.4158/ACCR-2020-0234. eCollection 2020 Nov-Dec.
Seizures following administration of potent bisphosphonates have been reported only sporadically in the medical literature. The rare cases described were often attributed to other precipitating factors such as hypoglycemia, acute infection, or predisposition to post-bisphosphonate hypocalcemia. We review the previous cases and present a new case of suspected seizure episode following zoledronic acid therapy.
We describe a case of a 63-year-old woman with a history of well-controlled epileptic disorder with no seizure activity in recent years. She was treated with intravenous zoledronic acid due to osteoporosis. Twelve hours after treatment, she suffered an episode of loss of consciousness with urinary incontinence suspected to be seizure-related.
Unlike previously reported cases, our patient had a low risk for postinfusion hypocalcemia as her creati-nine, calcium, parathyroid hormone, and vitamin D were all within normal limits prior to the infusion.
Our interpretation of the scenario described is based on clinical judgment and not supported by ancillary studies. Nevertheless, our case, along with the limitations described, joins other reports, and raises questions about possible interaction between a convulsion disorder and a potent bone resorption inhibition administration, leading to a relative hypocalcemia and possible seizure threshold reduction. This question should be further explored by other studies.
强效双膦酸盐给药后出现癫痫发作的情况在医学文献中仅有零星报道。所描述的罕见病例往往归因于其他诱发因素,如低血糖、急性感染或双膦酸盐治疗后低钙血症的易感性。我们回顾既往病例,并报告一例唑来膦酸治疗后疑似癫痫发作的新病例。
我们描述了一名63岁女性的病例,她有癫痫病史,近年来癫痫得到良好控制且无发作活动。因骨质疏松症,她接受了静脉注射唑来膦酸治疗后,治疗12小时后,她出现意识丧失并伴有尿失禁,怀疑与癫痫发作有关。
与既往报道的病例不同,我们的患者输注后发生低钙血症的风险较低,因为其肌酐、钙、甲状旁腺激素和维生素D水平在输注前均在正常范围内。
我们对此病例情况的解读基于临床判断,并未得到辅助检查的支持。尽管如此,我们的病例连同所描述的局限性,与其他报道一起,引发了关于惊厥性疾病与强效骨吸收抑制药物给药之间可能存在相互作用从而导致相对低钙血症和癫痫阈值可能降低的问题。这个问题应由其他研究进一步探讨。